1073129-57-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Chloro-6-trifluoroMethyl-nicotinic acid Methyl ester is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, 2-Chloro-6-trifluoroMethyl-nicotinic acid Methyl ester is used as a building block for the preparation of novel fungicidal agents. Its ability to inhibit the growth of certain fungi makes it a valuable component in the development of effective antifungal products.
Used in Materials Science:
2-Chloro-6-trifluoroMethyl-nicotinic acid Methyl ester is utilized in the field of materials science as a component in the preparation of various organic semiconductors and functional materials. Its unique properties contribute to the development of advanced materials with potential applications in electronics, optoelectronics, and other high-tech industries.

Upstream product

• 74-88-4 methyl iodide 
• 280566-45-2 2-chloro-6-(trifluoromethyl)pyridine-3-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1034131-62-8 methyl 2-(3,4-dimethoxybenzylamino)-6-(trifluoromethyl)nicotinate 

Relevant academic research and scientific papers

2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R1 represents a hydrogen atom, an optionally substituted alkyl group, or the like; R2 represents a hydrogen atom, a halogen atom, or the like; and R3 represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions (by machine translation)

[Problem] imidazole compound or its pharmacologically acceptable salt in the melanocortin receptor activity that operates as an active ingredient of a pharmaceutical composition comprising. "I" general formula [a]" Formula, the aryl group may be substituted A ring represents a; R1 Represents a hydrogen atom, or an alkyl group which may be substituted represented; R2 Represents a hydrogen atom, a halogen atom or represents a; R3 The alkyl group may be substituted " represented by the imidazole compound, its pharmacologically acceptable salt as an active ingredient in a pharmaceutical composition. [Drawing] no (by machine translation)

QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE

Compounds of Formula I are useful inhibitors of HIF prolyl hydroxylases. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF

Compounds of Formula (I) are useful as inhibitors of HIF prolyl hydroxylases where the definitions of the variables are provided herein.